Morgan Stanley reaffirmed their equal weight rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research report sent to investors on Friday morning. They currently have a $490.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $450.00.

REGN has been the topic of a number of other research reports. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 14th. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. Leerink Swann reiterated an outperform rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Citigroup Inc. increased their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a buy rating in a research report on Friday, August 4th. Finally, Credit Suisse Group lowered Regeneron Pharmaceuticals to a hold rating and set a $485.00 target price on the stock. in a research report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Hold and an average price target of $489.92.

Regeneron Pharmaceuticals (REGN) traded up 1.41% during trading on Friday, hitting $469.95. 986,046 shares of the stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The stock has a market cap of $49.83 billion, a P/E ratio of 47.15 and a beta of 1.62. The stock has a 50 day moving average price of $460.32 and a 200-day moving average price of $451.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the firm posted $2.82 EPS. The business’s revenue was up 21.2% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post $14.92 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Given “Equal Weight” Rating at Morgan Stanley” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-given-equal-weight-rating-at-morgan-stanley/1616192.html.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the transaction, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sanofi bought 166,415 shares of the company’s stock in a transaction on Thursday, August 24th. The stock was purchased at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. Insiders have sold a total of 89,468 shares of company stock valued at $42,312,448 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. grew its position in Regeneron Pharmaceuticals by 20.6% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after acquiring an additional 1,199 shares in the last quarter. Dupont Capital Management Corp acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $220,000. Blair William & Co. IL grew its position in Regeneron Pharmaceuticals by 4.8% in the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after acquiring an additional 79 shares in the last quarter. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 2.4% in the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after acquiring an additional 2,646 shares in the last quarter. Finally, National Pension Service grew its position in Regeneron Pharmaceuticals by 10.8% in the 2nd quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after acquiring an additional 6,481 shares in the last quarter. 67.95% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.